ERS clinical practice guidelines for the management of patients with idiopathic pulmonary fibrosis and lung cancer
In brief
Guideline offers 11 conditional treatment recommendations for lung cancer with idiopathic pulmonary fibrosis
The European Respiratory Society guideline suggests surgery for medically fit patients with early-stage cancer and chemotherapy for fit patients with advanced disease, but advises against concurrent radiation and chemotherapy because of very high rates of acute exacerbations. Recommendations for stereotactic radiation and immunotherapy are conditional, and evidence is insufficient for targeted therapy, underscoring the need to weigh risks and patient preferences in specialist teams.
- Journal
- The European respiratory journal (Q1)
- Published
- 19 November 2026
- Study design
- Practice guideline / consensus
- Evidence level
- Level 1, High (CEBM 1c)
- Authors
- Argyris Tzouvelekis, Merel E Hellemons, Charlotte Billiet, Torsten Gerriet Blum, Jacques Cadranel, Laura Fabbri, et al.
- PMID
- 43057869
- DOI
- 10.1183/13993003.01271-2026
Why clinicians should know about it
- Picked for Pulmonary and Respiratory Medicine (paper of the day, 20 November 2026): ERS guideline addresses lung cancer management in patients with IPF
- Picked for Radiation Oncology (paper of the day, 20 November 2026): Guideline addresses stereotactic radiotherapy and chemoradiation in IPF
Abstract
BACKGROUND: Managing patients with idiopathic pulmonary fibrosis (IPF) and concomitant lung cancer is a major clinical challenge due to increased incidence and negative impact on quality of life and mortality. Evidence-based recommendations are lacking. This European Respiratory Society (ERS) clinical practice guideline provides recommendations to balance oncological benefits against treatment-associated toxicity. METHODS: An ERS multidisciplinary Task Force of experts and patient representatives produced 11 conditional recommendations across seven PICO (Population, Intervention, Comparison, Outcome) questions and two narrative questions; for one PICO question no recommendation was issued. Systematic reviews were performed for each question. Evidence certainty was assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach (for PICOs) and recommendations were formulated using the Evidence-to-Decision framework. RESULTS: For early-stage lung cancer, the Task Force suggests surgical resection in medically fit patients. Postoperative risk necessitates systematic preoperative evaluation, perioperative antifibrotic therapy discussion and protective perioperative strategies. For stereotactic radiotherapy, a conditional recommendation for either the intervention or the comparison was issued, balancing potential oncological benefit against radiation pneumonitis. In locally advanced lung cancer, the Task Force suggests not administering concurrent radio-chemotherapy, due to very high acute exacerbation rates. For advanced lung cancer, chemotherapy is suggested in medically fit patients, where survival benefits outweigh increased toxicity risks. For stage IV lung cancer, evidence for immunotherapy was limited, thus a conditional recommendation for either the intervention or the comparison was issued. Evidence for targeted therapy for lung cancer in patients with IPF was insufficient to support a recommendation. CONCLUSION: Given the poor prognosis of both conditions and treatment-associated risks, management requires multidisciplinary assessment of competing risks and patient preferences in experienced interstitial lung disease and oncology centres.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.